Karyopharm Therapeut (KPTI) Stock Price, Quote & News

Company Profile

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for th...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 658 0600

Website: www.karyopharm.com

Address:

85 Wells Avenue, 2nd Floor, Suite 210, Newton, United States

Social_Idiot Feb. 4 at 2:13 AM

$KPTI This might pop a bit tomorrow.

1 · Reply

celebratelife Feb. 3 at 9:57 PM

$KPTI The incompetent or compromised Board just gave 32,415 stock options (RSU) to the worst general counsel in history, Mike Mano! When it comes to giving to themselves and others at the cost of shareholders, they never care.

0 · Reply

celebratelife Feb. 3 at 9:07 PM

$KPTI only option trade today was a bet on stock being over $10.80 by April.

0 · Reply

lovestockstwits Feb. 3 at 5:08 PM

$KPTI running

0 · Reply

celebratelife Feb. 3 at 4:14 PM

$KPTI One instance of buying around 40,000 shares at ask.

0 · Reply

celebratelife Feb. 2 at 9:11 PM

$KPTI I never forget every time Richard Paulson despicably and shamelessly announced delays, bad news after bad news. Shorts love him.

0 · Reply

CliffordCapital Feb. 2 at 8:18 PM

$KPTI Can we get a run down to 5.60$ before data?

1 · Reply

celebratelife Feb. 2 at 7:00 PM

$KPTI We cannot conclude there won't be a run up to the data but we can conclude that Richard Paulson is the lousiest, most irresponsible, most incompetent or possibly compromised CEO in the history of the universe.

0 · Reply

CliffordCapital Feb. 2 at 3:47 PM

$KPTI yes I agree with the poster below. Doesn’t look like a runup into data bc people are scared to get diluted.. and the ones jumping in are being met by the few getting out for the data release… fingers crossed for good data. Basically a coin flip at this point

0 · Reply

hbkstockislife Feb. 2 at 2:11 PM

$KPTI every stock in my portfolio ran except this one ..weird stock ..get a feeling there will be no run up to data ..Anywaz GL to all holding

0 · Reply

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jan 12, 2026, 7:00 AM EST - 22 days ago

Karyopharm Announces Preliminary Unaudited 2025 Revenue and Reiterates Expectation of Delivering Potentially Transformative Phase 3 Data in 2026

Dec 8, 2025, 7:00 AM EST - 2 months ago

Karyopharm to Participate in Baird's Biotech Discovery Series

Dec 1, 2025, 7:00 AM EST - 2 months ago

Karyopharm to Participate at the Piper Sandler 37th Annual Healthcare Conference

Nov 3, 2025, 1:26 PM EST - 3 months ago

Karyopharm Therapeutics Inc. (KPTI) Q3 2025 Earnings Call Transcript

Nov 3, 2025, 7:00 AM EST - 3 months ago

Karyopharm Reports Third Quarter 2025 Financial Results and Highlights Recent Company Progress

Oct 27, 2025, 7:00 AM EDT - 3 months ago

Karyopharm to Report Third Quarter 2025 Financial Results on November 3, 2025

Oct 8, 2025, 1:31 PM EDT - 4 months ago

Karyopharm Strengthens Balance Sheet With $100 Million Financing To Extend Cash Runway Into 2026

Oct 8, 2025, 7:00 AM EDT - 4 months ago

Karyopharm Announces Strategic Financing Transactions to Support Growth; Extends Cash Runway Into Second Quarter of 2026, Beyond Expected Top-Line Readout of Phase 3 SENTRY Trial in Myelofibrosis

Sep 10, 2025, 7:00 AM EDT - 5 months ago

Karyopharm Announces Completion of Enrollment in the Phase 3 SENTRY Trial in Myelofibrosis

Aug 11, 2025, 11:02 AM EDT - 6 months ago

Karyopharm Therapeutics Inc. (KPTI) Q2 2025 Earnings Call Transcript

Aug 11, 2025, 7:30 AM EDT - 6 months ago

Karyopharm Reports Second Quarter 2025 Financial Results and Highlights Recent Company Progress

Aug 5, 2025, 7:00 AM EDT - 6 months ago

Karyopharm to Report Second Quarter 2025 Financial Results on August 11, 2025

Jun 3, 2025, 8:00 AM EDT - 8 months ago

Karyopharm to Present at the Jefferies Global Healthcare Conference

May 19, 2025, 7:00 AM EDT - 9 months ago

Karyopharm to Participate at the 2025 RBC Capital Markets Global Healthcare Conference

May 14, 2025, 9:31 AM EDT - 9 months ago

Karyopharm Announces Poster Presentation on Selinexor in Myelofibrosis at the 2025 European Hematology Association Annual Meeting

May 13, 2025, 1:39 PM EDT - 9 months ago

These Analysts Revise Their Forecasts On Karyopharm Therapeutics After Q1 Results

May 13, 2025, 7:15 AM EDT - 9 months ago

Karyopharm Therapeutics Inc. (KPTI) Q1 2025 Earnings Call Transcript

May 12, 2025, 4:05 PM EDT - 9 months ago

Karyopharm Reports First Quarter 2025 Financial Results and Announces New Data in Myelofibrosis that Further Suggests Selinexor May Lead to Meaningful Spleen Volume Reduction, Symptom Improvement, Hemoglobin Stabilization and Disease Modification

May 8, 2025, 4:05 PM EDT - 9 months ago

Karyopharm to Report First Quarter 2025 Financial Results on May 12, 2025

Mar 5, 2025, 12:00 AM EST - 1 year ago

XPOVIO® (selinexor) Approved for Commercialization in Indonesia, Further Expanding Antengene's Commercial Presence in APAC

Feb 24, 2025, 8:40 AM EST - 1 year ago

Karyopharm Announces 1-for-15 Reverse Stock Split

Feb 19, 2025, 11:05 AM EST - 1 year ago

Karyopharm Therapeutics Inc. (KPTI) Q4 2024 Earnings Call Transcript

Feb 19, 2025, 7:30 AM EST - 1 year ago

Karyopharm Reports Fourth Quarter and Full Year 2024 Financial Results, Announces Update to Phase 3 XPORT-EC-042 Trial and Highlights Recent Company Progress

Feb 13, 2025, 4:30 AM EST - 1 year ago

Antengene Announces XPOVIO® Approved for Public Health Insurance Coverage in Taiwan Market, Benefiting More Patients with R/R MM in the Region

Feb 12, 2025, 7:00 AM EST - 1 year ago

Karyopharm to Report Fourth Quarter and Full Year 2024 Financial Results on February 19, 2025

Jan 13, 2025, 8:30 AM EST - 1 year ago

Karyopharm Announces Preliminary Unaudited 2024 Revenue and 2025 Objectives

Jan 2, 2025, 7:00 AM EST - 1 year ago

Karyopharm Announces the Appointment of Lori Macomber as Chief Financial Officer

Dec 9, 2024, 8:00 AM EST - 1 year ago

Karyopharm Announces the Appointment of Brendan Strong as Senior Vice President of Investor Relations and Corporate Communications

Dec 3, 2024, 7:00 AM EST - 1 year ago

Karyopharm Therapeutics Provides Endometrial Cancer Program Update

Nov 25, 2024, 7:00 AM EST - 1 year ago

Karyopharm to Participate at the Piper Sandler 36th Annual Healthcare Conference

Nov 20, 2024, 4:05 PM EST - 1 year ago

Karyopharm Therapeutics Announces the Appointment of Chief Accounting Officer

Nov 18, 2024, 7:00 AM EST - 1 year ago

Karyopharm to Present Selinexor Data at the 66th American Society of Hematology Annual Meeting and Exposition

Nov 5, 2024, 9:22 PM EST - 1 year ago

Karyopharm Therapeutics Inc. (KPTI) Q3 2024 Earnings Call Transcript

Nov 5, 2024, 7:30 PM EST - 1 year ago

Antengene to Present Results from Two Late-Stage Studies of Selinexor Signaling Potential Clinical Breakthrough at ASH 2024

Nov 5, 2024, 7:30 AM EST - 1 year ago

Karyopharm Reports Third Quarter 2024 Financial Results and Highlights Recent Company Progress

Oct 31, 2024, 8:00 AM EDT - 1 year ago

Karyopharm to Report Third Quarter 2024 Financial Results on November 5, 2024

Oct 31, 2024, 7:30 AM EDT - 1 year ago

Karyopharm Announces Favorable Change in Co-Primary Endpoint for Pivotal Phase 3 SENTRY Trial in Myelofibrosis

Oct 30, 2024, 4:30 PM EDT - 1 year ago

Karyopharm to Host Investor Event with Leading Myelofibrosis KOLs and Provide a Favorable Study Design Update on October 31, 2024

Oct 17, 2024, 10:35 PM EDT - 1 year ago

Antengene Announces XPOVIO® (selinexor) Approved for Its Third Indication in South Korea, Bringing Fresh Hope to Patients with MM in the Country

Sep 23, 2024, 5:00 AM EDT - 1 year ago

Antengene Announces XPOVIO® (selinexor) Approved for Commercialization in Thailand

Sep 3, 2024, 7:00 AM EDT - 1 year ago

Karyopharm to Participate at Upcoming Investor Conferences

Aug 6, 2024, 7:30 AM EDT - 1 year ago

Karyopharm Reports Second Quarter 2024 Financial Results and Highlights Recent Company Progress

Aug 5, 2024, 8:00 PM EDT - 1 year ago

Antengene Announces XPOVIO® (selinexor) Approved for Commercialization in Malaysia

Jul 31, 2024, 4:05 PM EDT - 1 year ago

Karyopharm to Report Second Quarter 2024 Financial Results on August 6, 2024

Jul 5, 2024, 9:10 AM EDT - 1 year ago

XPOVIO® (selinexor) Approved for New Indication in DLBCL in China, Bringing a New Treatment Option to Patients in the Country

Jun 26, 2024, 4:42 AM EDT - 1 year ago

Antengene Announces XPOVIO® (selinexor) National Health Insurance Service Approval for Reimbursement in South Korea

Jun 1, 2024, 1:45 PM EDT - 1 year ago

Karyopharm Presents Updated Exploratory Subgroup Analyses from SIENDO Study in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer During 2024 ASCO Plenary Series: Rapid Abstract Updates

May 29, 2024, 4:05 PM EDT - 1 year ago

Karyopharm to Participate at the Jefferies Global Healthcare Conference

May 8, 2024, 4:05 PM EDT - 1 year ago

Karyopharm to Participate at the 2024 RBC Capital Markets Global Healthcare Conference

Social_Idiot Feb. 4 at 2:13 AM

$KPTI This might pop a bit tomorrow.

1 · Reply

celebratelife Feb. 3 at 9:57 PM

0 · Reply

celebratelife Feb. 3 at 9:07 PM

$KPTI only option trade today was a bet on stock being over $10.80 by April.

0 · Reply

lovestockstwits Feb. 3 at 5:08 PM

$KPTI running

0 · Reply

celebratelife Feb. 3 at 4:14 PM

$KPTI One instance of buying around 40,000 shares at ask.

0 · Reply

celebratelife Feb. 2 at 9:11 PM

$KPTI I never forget every time Richard Paulson despicably and shamelessly announced delays, bad news after bad news. Shorts love him.

0 · Reply

CliffordCapital Feb. 2 at 8:18 PM

$KPTI Can we get a run down to 5.60$ before data?

1 · Reply

celebratelife Feb. 2 at 7:00 PM

0 · Reply

CliffordCapital Feb. 2 at 3:47 PM

0 · Reply

hbkstockislife Feb. 2 at 2:11 PM

$KPTI every stock in my portfolio ran except this one ..weird stock ..get a feeling there will be no run up to data ..Anywaz GL to all holding

0 · Reply

celebratelife Jan. 30 at 11:09 PM

$KPTI the only stock in the universe whose lousy CEO GIVES AWAY money he raises with toxic financing and dilution to the detriment of shareholders, and has destroyed a BILLION DOLLARS in shareholder value by repeatedly effectively saying FUCK YOU to shareholders as he gets paid MILLIONS despite catastrophic performance, and the lousy Board don't fire him despite year after year of that shit which is stinky fishy rotten. BUT someones are happy: Shorts Crooks Cockroaches for whom this CEO and Board are DREAM COME TRUE have made a killing at shareholder cost. Our nightmare CEO and Board is a gift to shorts. Us bagholders are still holding and looking at a 90%+ loss as these dorks' bank accounts have grown by millions, and we will hold this lousy CEO Richard Paulson & Board led by Barry Greene and that horrible General Counsel Mike Mano accountable and liable if they don't manage to turn this around. Of course they should have fired Paulson years ago but something stinky fishy is going on.

1 · Reply

CliffordCapital Jan. 30 at 10:55 PM

$KPTI Might have been Affinity pulling the price from $9 down to $6 to accumulate. Their 13G shows they held >5% as of Jan 22, shortly after that brutal selloff. Once crossing 5%, they’re required to file within 10 calendar days. Looks like institutional accumulation, not random dumping

0 · Reply

CliffordCapital Jan. 30 at 10:49 PM

$KPTI Affinity Advisors LLC increased their stake massively in the recent weeks. Gives me confidence in the upcoming readout. They hold around 10M $ worth of $KPTI stock.

0 · Reply

SunriseMorning Jan. 30 at 9:01 PM

$KPTI only stock in universe which didn’t run to data ..rest all runs 100-200% before data

2 · Reply

celebratelife Jan. 30 at 2:28 PM

$KPTI More insight on yesterday's put trades: I consulted with ChatGPT which gave me this: It's likely a short near-term put + long longer-term spread (long put calendar spread) which is bullish or neutral but not bearish.

0 · Reply

hbkstockislife Jan. 30 at 1:42 PM

$KPTI dang tutes buying ..Affinity increase their position by 8.6% as per 13G Last night

0 · Reply

Watson66 Jan. 29 at 10:25 PM

$KPTI

0 · Reply

celebratelife Jan. 29 at 10:16 PM

$KPTI

0 · Reply

celebratelife Jan. 29 at 9:16 PM

$KPTI Today's put action

0 · Reply

hbkstockislife Jan. 29 at 8:59 PM

$KPTI basically ran down to data ..sad ..I honestly thought it would be 15-20$ by now ..Anywaz onto next one .GL

0 · Reply

celebratelife Jan. 29 at 7:59 PM

$KPTI someone's gambling with puts today, risking about $100,000 hoping the stock won't drop below 6 and not above 9.50 so he can make between 50k to 86k. if price goes below 6 or above 9.50 he loses about 100k. In other words, counting on no volatility before MF data.

1 · Reply

celebratelife Jan. 29 at 4:10 PM

$KPTI 6.98 down to 6.75 on virtually no volume. Playing field for the manipulators and crooks thanks to dorks like Mike Mano and Richard Paulson and Barry Greene et al. who've ruined a great company as they got richer and richer themselves.

0 · Reply

Market Cap	119.38M
Revenue (ttm)	145.24M
Net Income (ttm)	-76.42M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-52.62%
Debt to Equity Ratio	-0.36

Volume	485,400
Avg Vol	309,846
Day's Range	N/A - N/A
Shares Out	18.31M
Stochastic %K	42%
Beta	0.21
Analysts	Strong Sell
Price Target	$14.67